# Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects

> **NCT00352911** · PHASE2 · COMPLETED · sponsor: **VGX Pharmaceuticals, LLC** · enrollment: 19 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** VGX-410 (Mifepristone)
- **DRUG:** Placebo for VGX-410 (Mifepristone)

## Key facts

- **NCT ID:** NCT00352911
- **Lead sponsor:** VGX Pharmaceuticals, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-06
- **Final completion:** 2007-11
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2010-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00352911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00352911, "Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00352911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*